Skip to main content
. 2020 Feb 19;135(19):1650–1660. doi: 10.1182/blood.2019002936

Table 2.

Comparison of response and toxicity between the Con-ibr and No-ibr cohorts

Con-ibr cohort No-ibr cohort P*
Response at 4 wk
 iwCLL 2018, CR/CRi/PR 15/18 (83) 10/18 (56) .15
 iwCLL 2018 CT response, CR/PR 10/14 (71) 9/17 (53) .46
 Marrow CR by flow cytometry 13/18 (72) 12/18 (67) 1
 Marrow CR by IGH sequencing§ 11/13 (85) 6/10 (60) .34
Toxicity
 CRS grade
 Median (range) 1 (0-2) 2 (0-5) .04
 Any grade CRS 14/19 (74) 18/19 (95) .49
 Grade ≥3 CRS 0/19 (0) 2/19 (11) .18
Neurotoxicity grade
 Median (range) 0 (0-3) 0 (0-5) .33
 Any grade neurotoxicity 5/19 (26) 8/19 (42) .49
 Grade ≥3 neurotoxicity 5/19 (26) 7/19 (37) .73
 Grade 5 (fatal) events Presumed ibrutinib-related cardiac arrhythmia (n = 1) CRS and neurotoxicity (n =1) Not applicable

Unless otherwise noted, data are n/N (%).

*

Two-sided P values calculated using the Fisher’s exact test.

Two patients were not evaluable for response (early death before first disease restaging).

In patients with measurable nodal disease by CT.

§

In patients with no detectable disease by flow cytometry and with a trackable clone.

HHS Vulnerability Disclosure